Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy: Shedding Light on Their Clinical Potential

Authors

Shiavax J. Rao, Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA.
Beani Forst, Department of Medicine, Creighton University Arizona Health Education Alliance, Phoenix, Az, USA.
Amreen K. Kanwal, Tufts University School of Medicine, Boston, MA, USA.
Arjun Kanwal, Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA.
Wilbert S. Aronow, Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USA.Follow
Srihari S. Naidu, Hypertrophic Cardiomyopathy Center, Cardiac Catheterization Laboratory, Department of Cardiology, Westchester Medical Center and Department of Medicine, New York Medical College, Valhalla, NY, USA.

Author Type(s)

Resident/Fellow, Faculty

DOI

10.1080/13543784.2023.2166825

Journal Title

Expert Opinion on Investigational Drugs

First Page

1

Last Page

4

Document Type

Article

Publication Date

1-1-2023

Department

Medicine

Recommended Citation

Rao, S. J., Forst, B., Kanwal, A. K., Kanwal, A., Aronow, W. S., & Naidu, S. S. (2023). Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy: Shedding Light on Their Clinical Potential. Expert Opinion on Investigational Drugs, 32 (1), 1-4. https://doi.org/10.1080/13543784.2023.2166825